Importantly, since glioblastoma lines with Msi1 KO displayed increased sensitivity to cell cycle and DNA replication inhibitors, we propose that a drug combination strategy (Msi1 + cell cycle/DNA replication inhibitors) could be a viable treatment option for GBM patients. Here, MSI1 is linked to glioblastoma.